HR Execs on the Move

Endo

www.endo.com

 
Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo`s strategy is to centralize and unify our business, driving productivity improvements. We will focus ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.endo.com
  • 1400 Atwater Drive
    Malvern, PA USA 19355
  • Phone: 484.216.0000

Executives

Name Title Contact Details
Monette Ablan
 Senior Director, Enterprise Compensation Profile
Rosalie Filling
 Vice President, Global Head R&D Operations Profile
Henry Wolfe
 Vice President, Biologics Research & Development Profile
James Tursi
 Executive Vice President, Global Research and Development Profile
Matthew Davis
 Chief Scientific Officer, SVP Global Branded R&D Profile

Jobs

Chief Information Security Officer

Endo Malvern, PA

Similar Companies

Revive Therapeutics

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

Canadian Phamacy Online

Canadian Phamacy Online is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.

Apnimed

Apnimed is a clinical-stage company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders.

AMGIT

AMGIT is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.